Home Hedge Funds CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Update

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Update

41
0
CytomX Therapeutics logo

CytomX Therapeutics, Inc. (NASDAQ:CTMXGet Rating) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 894,100 shares, a decline of 14.0% from the August 15th total of 1,040,000 shares. Currently, 1.4% of the company’s shares are sold short. Based on an average trading volume of 1,810,000 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CTMX. Cowen cut shares of CytomX Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 11th. Wedbush downgraded shares of CytomX Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $6.00 to $2.00 in a research report on Thursday, July 7th. StockNews.com upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 5th. HC Wainwright cut shares of CytomX Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, July 11th. Finally, Mizuho downgraded shares of CytomX Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $16.00 to $4.00 in a report on Thursday, July 7th. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $4.89.

Hedge Funds Weigh In On CytomX Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Clearline Capital LP lifted its position in CytomX Therapeutics by 3.1% during the second quarter. Clearline Capital LP now owns 196,583 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 5,983 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of CytomX Therapeutics by 3.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 207,071 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 6,872 shares during the last quarter. Raymond James Financial Services Advisors Inc. acquired a new position in shares of CytomX Therapeutics during the 4th quarter worth about $44,000. Gladius Capital Management LP purchased a new stake in CytomX Therapeutics during the 2nd quarter valued at about $25,000. Finally, Mackenzie Financial Corp purchased a new stake in CytomX Therapeutics during the 1st quarter valued at about $35,000. 84.38% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Stock Down 4.8 %

Shares of NASDAQ CTMX traded down $0.08 during midday trading on Friday, reaching $1.58. The company had a trading volume of 402,026 shares, compared to its average volume of 625,025. The firm’s fifty day moving average price is $1.54 and its 200-day moving average price is $1.97. The stock has a market cap of $104.20 million, a PE ratio of -1.06 and a beta of 0.47. CytomX Therapeutics has a one year low of $1.19 and a one year high of $7.53.

CytomX Therapeutics (NASDAQ:CTMXGet Rating) last released its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.01). CytomX Therapeutics had a negative net margin of 133.42% and a negative return on equity of 121.88%. The business had revenue of $18.17 million during the quarter, compared to the consensus estimate of $18.43 million. As a group, equities research analysts expect that CytomX Therapeutics will post -1.16 EPS for the current year.

CytomX Therapeutics Company Profile

(Get Rating)

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company’s product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider CytomX Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and CytomX Therapeutics wasn’t on the list.

While CytomX Therapeutics currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source link

Previous articleBillionaire Andrew Forrest eyes stake in Rugby Australia
Next articleWhy Hedge Funds Are Piling In These 2 High Yielding Stocks – Wells Fargo (NYSE:WFC), Merck & Co (NYSE:MRK)

LEAVE A REPLY

Please enter your comment!
Please enter your name here